Sign In
Buy EOLS
$6.03
-0.140 (-2.27%)
At Close: Jun 03, 2026
Evolus to Participate in The Jefferies Global Healthcare Conference
08:30am, Tuesday, 19'th May 2026
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its man
Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe
08:30am, Monday, 11'th May 2026
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that the co
Evolus, Inc. (EOLS) Q1 2026 Earnings Call Transcript
02:13am, Tuesday, 05'th May 2026
Evolus, Inc. (EOLS) Q1 2026 Earnings Call Transcript
Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates
08:30pm, Monday, 04'th May 2026
Evolus, Inc. (EOLS) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.18 per share a year ago.
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financi
Evolus Targets Double-Digit Growth, Full-Year Profitability at Needham Healthcare Conference
04:02am, Friday, 17'th Apr 2026
Evolus (NASDAQ: EOLS) executives told investors at Needham and Company's 25th Annual Healthcare Conference that the company is pursuing double-digit growth and a transition to full-year profitability
Evolus to Report First Quarter Financial Results on May 4, 2026
08:30am, Tuesday, 14'th Apr 2026
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will repor
JPMorgan Chase & Co. Decreases Stake in Evolus, Inc. $EOLS
04:45am, Monday, 06'th Apr 2026
JPMorgan Chase and Co. decreased its holdings in Evolus, Inc. (NASDAQ: EOLS) by 35.5% in the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor ow
Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference
08:00am, Tuesday, 31'st Mar 2026
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its man
Evolus (NASDAQ:EOLS) Insider Sells $14,815.25 in Stock
05:26am, Monday, 23'rd Mar 2026
Evolus, Inc. (NASDAQ: EOLS - Get Free Report) insider Rui Avelar sold 3,119 shares of the firm's stock in a transaction that occurred on Friday, March 20th. The stock was sold at an average price of $
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 20'th Mar 2026
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS) a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant during Mar
Evolus Sees Toxin Market Stabilizing, Evolysse Gaining Traction, Raises 2028 Revenue Targets at Conference
02:32am, Tuesday, 17'th Mar 2026
Evolus (NASDAQ: EOLS) executives said they are seeing signs of stabilization and improvement in the U.S. botulinum toxin market after a period of industry-wide pressure, while describing a slower reco
Evolus, Inc. (NASDAQ:EOLS) Receives $17.50 Average Target Price from Analysts
01:10am, Thursday, 05'th Mar 2026
Shares of Evolus, Inc. (NASDAQ: EOLS - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seven analysts that are covering the stock, Marketbeat Ratings reports. One ana
Why Evolus Stock Soared Today
10:45pm, Wednesday, 04'th Mar 2026
Demand for Evolus' beauty products is growing. Management expects to generate sustainable profits in 2026.
Evolus, Inc. (EOLS) Q4 2025 Earnings Call Transcript
02:42am, Wednesday, 04'th Mar 2026
Evolus, Inc. (EOLS) Q4 2025 Earnings Call Transcript
